» Articles » PMID: 36224528

Improving Chronic Kidney Disease Detection and Treatment in the United States: the Chronic Kidney Disease Cascade of Care (C) Study Protocol

Abstract

Background: There are major gaps in the implementation of guideline-concordant care for persons with chronic kidney disease (CKD). The CKD Cascade of Care (C) initiative seeks to improve CKD care by improving detection and treatment of CKD in primary care.

Methods: C is a multi-modal initiative deployed in three major academic medical centers within the Department of Veterans Affairs (VA) Health Care System: San Francisco VA, San Diego VA, and Houston VA. The main objective of the first phase of C described in this protocol is to establish the infrastructure for universal CKD detection among primary care patients at high-risk for CKD with a triple-marker screen comprising cystatin C, creatinine, and albuminuria. Across the three sites, a comprehensive educational intervention and the integration of primary care-based clinical champions will be employed with the goal of improving CKD detection and treatment. The San Francisco VA will also implement a practice-facilitation intervention leveraging telehealth and health informatics tools and capabilities for enhanced CKD detection. Parallel formative evaluation across the three sites will assess the feasibility and acceptability of integrating cystatin C as part of routine CKD detection in primary care practice. The effectiveness of the interventions will be assessed using a pre-post observational design for change in the proportion of patients tested annually for CKD. Secondary outcomes will assess change in the initiation of cardio-kidney protective therapies and in nephrology referrals of high-risk patients.

Discussion: The first phase of C is a multi-facility multi-modal initiative that aims to improve CKD care by implementing a triple-marker screen for enhanced CKD detection in primary care.

Citing Articles

Rosmarinic acid attenuated inflammation and apoptosis in folic acid-induced renal injury: Role of FoxO3/ NFκB pathway.

Mottaghi M, Heidari F, Komeili Movahed T, Eidi A, Moslehi A Iran J Basic Med Sci. 2025; 28(3):316-322.

PMID: 39906624 PMC: 11790193. DOI: 10.22038/ijbms.2024.80551.17436.


A retrospective multi-site examination of chronic kidney disease using longitudinal laboratory results and metadata to identify clinical and financial risk.

Fung M, Haghamad A, Montgomery E, Swanson K, Wilkerson M, Stathakos K BMC Nephrol. 2024; 25(1):447.

PMID: 39639199 PMC: 11622455. DOI: 10.1186/s12882-024-03869-4.


Best-Practice Perspectives on Improving Early Detection and Management of Chronic Kidney Disease Associated With Type 2 Diabetes in Primary Care.

Goldman J, Busch R, Miller E Clin Diabetes. 2024; 42(3):429-442.

PMID: 39015171 PMC: 11247041. DOI: 10.2337/cd23-0074.


Cystatin C Use for CKD Detection in the Veterans Health Administration System: A Qualitative Study of Barriers and Facilitators.

Lamprea-Montealegre J, Shapiro A, Bontrager N, Rifkin D, Jassal S, Gregg L Kidney Med. 2024; 6(6):100830.

PMID: 38799784 PMC: 11127258. DOI: 10.1016/j.xkme.2024.100830.

References
1.
Tai-Seale M, McGuire T, Zhang W . Time allocation in primary care office visits. Health Serv Res. 2007; 42(5):1871-94. PMC: 2254573. DOI: 10.1111/j.1475-6773.2006.00689.x. View

2.
Diamantidis C, Hale S, Wang V, Smith V, Hudson Scholle S, Maciejewski M . Lab-based and diagnosis-based chronic kidney disease recognition and staging concordance. BMC Nephrol. 2019; 20(1):357. PMC: 6744668. DOI: 10.1186/s12882-019-1551-3. View

3.
Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

4.
Lees J, Welsh C, Celis-Morales C, Mackay D, Lewsey J, Gray S . Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nat Med. 2019; 25(11):1753-1760. PMC: 6858876. DOI: 10.1038/s41591-019-0627-8. View

5.
. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225):709-733. PMC: 7049905. DOI: 10.1016/S0140-6736(20)30045-3. View